MoneyWorks4Me

Ajanta Pharma informs about disclosure

27 Jan 2023 Evaluate
Ajanta Pharma has informed that exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 25, 2023 for Aayush Agrawal, trustee Aayush Agrawal Trust.

The above information is a part of company’s filings submitted to BSE.

Ajanta Pharma Share Price

3555.00 14.30 (0.40%)
28-Aug-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1917.80
Dr. Reddys Labs. 1183.00
Cipla 1414.00
Lupin 2167.10
Zydus Lifesciences 1180.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: